Texas Permanent School Fund Corp boosted its holdings in Catalent, Inc. (NYSE:CTLT – Free Report) by 46.2% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 37,381 shares of the company’s stock after acquiring an additional 11,812 shares during the period. Texas Permanent School Fund Corp’s holdings in Catalent were worth $2,456,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors and hedge funds have also recently modified their holdings of CTLT. Compagnie Lombard Odier SCmA acquired a new stake in shares of Catalent during the 4th quarter worth $34,000. FNY Investment Advisers LLC acquired a new stake in shares of Catalent during the first quarter valued at about $34,000. TCTC Holdings LLC bought a new position in Catalent in the 4th quarter valued at approximately $50,000. Eagle Bay Advisors LLC boosted its position in Catalent by 138.9% during the 4th quarter. Eagle Bay Advisors LLC now owns 1,254 shares of the company’s stock worth $56,000 after buying an additional 729 shares during the period. Finally, Allworth Financial LP increased its stake in shares of Catalent by 107.3% in the first quarter. Allworth Financial LP now owns 852 shares of the company’s stock valued at $56,000 after buying an additional 441 shares during the period.
Analyst Upgrades and Downgrades
Several analysts have recently commented on the company. UBS Group reduced their target price on Catalent from $60.00 to $55.00 in a research note on Tuesday, June 13th. Morgan Stanley lowered their price target on shares of Catalent from $85.00 to $50.00 in a report on Monday, May 22nd. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $49.00 price objective on shares of Catalent in a research report on Friday, June 30th. Bank of America increased their price objective on shares of Catalent from $28.00 to $33.00 in a research note on Tuesday, June 13th. Finally, TheStreet lowered shares of Catalent from a “c” rating to a “d+” rating in a research report on Monday, June 12th. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $56.25.
Catalent Stock Performance
Catalent (NYSE:CTLT – Get Free Report) last posted its quarterly earnings data on Monday, June 12th. The company reported ($0.12) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.08. Catalent had a net margin of 0.93% and a return on equity of 7.13%. The company had revenue of $1.04 billion during the quarter, compared to analysts’ expectations of $930.44 million. As a group, research analysts expect that Catalent, Inc. will post 0.84 earnings per share for the current year.
Insider Activity at Catalent
In other news, insider Manja Boerman sold 1,446 shares of the business’s stock in a transaction that occurred on Monday, May 1st. The shares were sold at an average price of $49.86, for a total transaction of $72,097.56. Following the completion of the sale, the insider now owns 14,414 shares in the company, valued at approximately $718,682.04. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other Catalent news, insider Manja Boerman sold 1,446 shares of the stock in a transaction dated Monday, May 1st. The shares were sold at an average price of $49.86, for a total value of $72,097.56. Following the completion of the transaction, the insider now directly owns 14,414 shares of the company’s stock, valued at $718,682.04. The sale was disclosed in a filing with the SEC, which is available at this link. Also, SVP Mario Gargiulo sold 678 shares of the company’s stock in a transaction on Monday, May 1st. The shares were sold at an average price of $49.86, for a total value of $33,805.08. Following the completion of the sale, the senior vice president now owns 5,676 shares in the company, valued at $283,005.36. The disclosure for this sale can be found here. Company insiders own 0.58% of the company’s stock.
Catalent Company Profile
Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
Featured Stories
- Five stocks we like better than Catalent
- Best Stocks Under $5.00
- Is AI On The Verge Of A Monster Short Squeeze Breakout?
- Which Wall Street Analysts are the Most Accurate?
- Chipotle Mexican Grill Serves Up Another Entry PointÂ
- Where to Find Earnings Call Transcripts
- 7 Best Hotel REITs to Buy Now
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.
